Iron removal as a potential cancer therapy

February 27, 2018, Okayama University
Iron chelators Deferasirox and Deferoxamine (DFO) suppress the expression of stemness marker. 5-FU, ordinary anti-cancer drug, did not inhibited. Credit: Okayama University

Researchers at Okayama University report in Oncotarget a promising method for targeting cancer stem cells that cause tumor growth and cancer relapse. The approach involves administering molecules that capture iron, an overload of which is known to be a potential cause of cancer.

Cancer stem cells (CSCs) are similar to normal stem cells in that they can differentiate—become cells of a specialized type. CSCs are resistant to radio- and chemotherapy and are believed to play an important role in metastasis and . Since iron overload is known to cause certain types of cancer, Dr. Toshiaki Ohara and Dr. Takayuki Ninomiya from Okayama University and colleagues have now tested whether the suppressing of iron levels can halt proliferation and 'stemness' of CSCs. The researchers found that controlled iron depletion indeed has the potential to become a therapy for targeting CSCs.

Dr. Ohara and colleagues first confirmed that in vitro, a supply of iron leads to the proliferation of CSCs, as well as the persistence of their stemness. Then, the researchers studied the effect of administering iron chelators: organic compounds that bond to particular metals, in this case iron. The scientists reckoned that through chelation, iron atoms are isolated and, potentially, 'neutralized'. Two known iron chelators were tested: deferasirox and deferoxamine. Both compounds suppressed the proliferation of a set of mouse cancer cells. The associated fibroblasts (cells that play a key role in cancer progression and believed to originate from CSCs), however, were not affected.

Regarding the mechanism causing the suppression of CSC proliferation, Dr. Ohara and colleagues found that the iron chelators induced apoptosis (a highly regulated process leading to cell death). The scientists also studied the effect of deferasirox and deferoxamine on the CSCs' stemness, and observed that the expression of stemness markers was suppressed—indirect evidence for stemness loss. The latter property was not observed in chemotherapy treatment, indicating the unique function of iron chelators as stemness marker suppressors. Finally, the researchers tested the effect of deferasirox and deferoxamine in vivo; both iron chelators suppressed CSC tumor growth and stemness marker expression.

The results of Dr. Ohara and colleagues show that the use of iron chelators could develop into an effective cancer treatment, complementary to standard chemotherapy. In the words of the researchers: "Although … the mechanisms [of stemness marker expression] are currently unknown … this study may represent an important first step in the development of novel iron chelation based strategies for CSC therapy."

Cancer stem cells

A (CSC) is a cancerous cell with the property of a normal stem cell that it can differentiate in various cell types found in a particular cancer sample. CSCs are tumor-forming, and cancer therapies targeting them are being developed, as CSCs are involved in cancer metastasis and tumor relapse.

Dr. Ohara from Okayama University and colleagues have now shown that controlled iron depletion in tumors is a promising novel strategy for targeting CSCs.

Chelation

Chelation is a type of bond between metal ions and molecules or molecular ions. It involves a multiple-bonded ligand binding to the metal ion; the ligand is usually an organic compound and called a chelant or chelator.

Since iron overload in the human body can lead to the formation of free radicals, which in turn can cause cancer, Dr. Ohara and colleagues investigated whether iron depletion through chelation, using the chelators deferasirox and deferoxamine, can suppress the proliferation and stemness of cancer stem .

Explore further: Stemming the spread of cancer

More information: Takayuki Ninomiya et al. Iron depletion is a novel therapeutic strategy to target cancer stem cells, Oncotarget (2017). DOI: 10.18632/oncotarget.21846

Related Stories

Stemming the spread of cancer

September 21, 2012
Okayama University's Masaharu Seno and colleagues have demonstrated in vitro the development of cancer stem cells (CSCs) from a type of normal stem cell exposed to their hypothetical microenvironment of a tumor.

Targeting bladder cancer's Achilles heel: stem cells

January 24, 2018
Two different proteins work separately as well as synergistically to feed a small pool of stem cells that help bladder cancer resist chemotherapy, research led by a Johns Hopkins Kimmel Cancer Center scientist suggests. The ...

HDAC inhibitors show promise against cancer stem cells

October 3, 2016
A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the potential to eliminate ...

Method identified to boost detection of highly cancerous stem cells

March 30, 2017
Japanese researchers identify process to improve fluorescence detection of cancer stem cells, which are primarily responsible for brain tumor progression and recurrence after treatment

Recommended for you

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

jhnycmltly
not rated yet Mar 01, 2018
Anyone planning on lowering their iron levels by phlebotomy should remember the hemoglobin the medical profession accepts as normal, seems, to be too high, because, the marker for inflammation begins below that marker, normal.
"Abnormal ALT started to occur if hemoglobin >11 g/dl in females or >13.5 g/dl in males"

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.